FDA expands indication of BI inhaler to include maintenance treatment of asthma – FierceDrugDelivery

FDA expands indication of BI inhaler to include maintenance treatment of asthma
FierceDrugDelivery
The only inhaler that administers a slow-moving mist to help respiratory patients inhale the medication is now FDA-approved for the long-term maintenance treatment of asthma, in addition to its previous indication to treat COPD. The expanded indication
FDA Approves New Indication for Boehringer's Spiriva RespimatDrug Discovery & Development
Landmark year for Boehringer Ingelheim's respiratory portfolio – new data for The FINANCIAL
ERS 2015: Landmark year for Boehringer Ingelheim's respiratory portfolio – new Business Wire (press release)

all 15 news articles »

View full post on asthma – Google News